PMID- 28415646
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 19
DP  - 2017 May 9
TI  - Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 
      translocation RCC: comparison of three different diagnostic methods.
PG  - 30756-30765
LID - 10.18632/oncotarget.16481 [doi]
AB  - We evaluated the frequency of translocation renal cell carcinoma (RCC) by reverse 
      transcription polymerase chain reaction (RT-PCR) and how well the TFE3 
      immunoreactivity is concordant with TFE3 gene translocation status proved by 
      fluorescence in situ hybridization (FISH) assay and RT-PCR. TFE3 and Cathepsin K 
      expression was analyzed by immunohistochemistry in 185 RCC cases, and 48 cases 
      either of more than weak expression of TFE3 or of positivity for Cathepsin K were 
      done for FISH analysis and RT-PCR. All the RT-PCR positive cases were confirmed 
      by cloning and sequencing. Of the 14 cases with strong nuclear TFE3 expression, 
      12 showed a break-apart signal by FISH. ASPL- and PRCC-TFE3 translocations were 
      detected in 13 and one case, respectively, by RT-PCR. Of 21 cases with weak TFE3 
      expression, five were translocation-positive by FISH. ASPL-, PRCC-, and PSF-TFE3 
      translocations were detected by RT-PCR (n=3, 3, and 1, respectively). All 13 
      TFE3-negative/cathepsin K-positive cases were negative by FISH and two each 
      harbored ASPL- and PRCC-TFE3 translocations that were detected by RT-PCR. A high 
      rate of TFE3 immunoreactivity (8.6%) was confirmed by RT-PCR (13.5%) and FISH 
      (9.7%). Higher translocation rate of RT-PCR means RT-PCR detected translocation 
      in TFE3 weak expression group and only cathepsin K positive group more 
      specifically than FISH. Thus, RT-PCR would complement FISH analysis for detecting 
      translocation RCC with fusion partners.
FAU - Lee, Hyun Jung
AU  - Lee HJ
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
AD  - Research Institute for Convergence of Biomedical Science and Technology, Pusan 
      National University Yangsan Hospital, Yang San, Korea.
FAU - Shin, Dong Hoon
AU  - Shin DH
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
AD  - Research Institute for Convergence of Biomedical Science and Technology, Pusan 
      National University Yangsan Hospital, Yang San, Korea.
FAU - Noh, Gyu You
AU  - Noh GY
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Kim, Young Keum
AU  - Kim YK
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Kim, Ahrong
AU  - Kim A
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Shin, Nari
AU  - Shin N
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Lee, Jung Hee
AU  - Lee JH
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Choi, Kyung Un
AU  - Choi KU
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Kim, Jee Yeon
AU  - Kim JY
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Lee, Chang Hun
AU  - Lee CH
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Sol, Mee Young
AU  - Sol MY
AD  - Department of Pathology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
FAU - Rha, Seo Hee
AU  - Rha SH
AD  - Department of Pathology, Donga University Hospital, Busan, Korea.
FAU - Park, Sung Woo
AU  - Park SW
AD  - Department of Urology, School of Medicine, Pusan National University, Yangsan, 
      Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (TFE3 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics/metabolism
MH  - Biomarkers, Tumor
MH  - Carcinoma, Renal Cell/*diagnosis/*genetics/metabolism
MH  - *Chromosomes, Human, X
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Incidence
MH  - Kidney Neoplasms/*diagnosis/*genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *Translocation, Genetic
PMC - PMC5458165
OTO - NOTNLM
OT  - FFPE
OT  - FISH
OT  - Pathology Section
OT  - RT-PCR
OT  - TFE3
OT  - renal cell carcinoma
COIS- CONFLICTS OF INTEREST The authors declare no potential conflicts of interest in 
      the article.
EDAT- 2017/04/19 06:00
MHDA- 2018/03/06 06:00
PMCR- 2017/05/09
CRDT- 2017/04/19 06:00
PHST- 2017/01/12 00:00 [received]
PHST- 2017/03/15 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
PHST- 2017/05/09 00:00 [pmc-release]
AID - 16481 [pii]
AID - 10.18632/oncotarget.16481 [doi]
PST - ppublish
SO  - Oncotarget. 2017 May 9;8(19):30756-30765. doi: 10.18632/oncotarget.16481.